|Over a month ago|
Fly Intel: After Hours Movers » 19:0502/2502/25/20
ACRS, WW, MTDR, BGS, ALRM, NVRO, INFN, EVH, PRTK, ADMS, AKCA, SDC, RVLV, SUPN, PODD, SCCO, TOL, VICR, PEN, UIS, PLNT, SPCE, REAL, ORA, IOVA, EXEL, EVTC, CRM, JAZZ, CZR, AMRN, RRGB, VNDA, DIS
UP AFTER EARNINGS:…
UP AFTER EARNINGS: Aclaris (ACRS) up 8.0%... WW International (WW) up 6.8%... Matador Resources (MTDR) up 6.0%... B&G Foods (BGS) up 5.7%... Alarm.com (ALRM) up 5.3%... Nevro (NVRO) up 3.4%... Infinera (INFN) up 3.4%... Evolent Health (EVH) up 3.1%... Paratek Pharma (PRTK) up 2.8%... Adamas Pharma (ADMS) up 1.9%... Akcea Therapeutics (AKCA) up 1.9%. DOWN AFTER EARNINGS: SmileDirectClub (SDC) down 20.5%... Revolve Group (RVLV) down 18.1%... Supernus Pharma (SUPN) down 15.0%... Insulet (PODD) down 12.1%... Southern Copper (SCCO) down 9.3%... Toll Brothers (TOL) down 9.0%... Vicor Corp (VICR) down 8.7%... Penumbra (PEN) down 6.9%... Unisys (UIS) down 6.1%... Planet Fitness (PLNT) down 5.9%... Virgin Galactic (SPCE) down 5.7%... RealReal (REAL) down 5.1%... Ormat Technologies (ORA) down 3.8%... Iovance Biotherapeutics (IOVA) down 3.1%... Exelixis (EXEL) down 3.1%... Evertec (EVTC) down 3.0%... Salesforce (CRM) down 2.1%... Jazz Pharma (JAZZ) down 1.8%... Caesars (CZR) down 1.6%... Amarin Corp (AMRN) down 1.4%... Red Robin (RRGB) down 1.3%. ALSO LOWER: Vanda Pharma (VNDA) down 7.6% after Phase 3 study of tradipitant did not meet primary endpoint... Disney (DIS) down 1.7% after naming new CEO. Movers as of 18:30ET.
Adamas Pharmaceuticals reports Q4 EPS (83c), consensus (85c) » 16:1902/2502/25/20
Reports Q4 revenue…
Reports Q4 revenue $16.3M, consensus $15.49M. "The progress we made last year treating Parkinson's disease patients with dyskinesia created a strong foundation to build upon in 2020," said Neil F. McFarlane, Chief Executive Officer of Adamas. "The confidence we have in our growth strategy for GOCOVRI is bolstered by positive physician feedback, our recent patent settlement, strong patient persistence, and newly published open-label data demonstrating patients taking GOCOVRI in a real-world setting experienced reductions in both dyskinesia and OFF time sustained for at least two years."
Fly Insider: Avis, Cabot Microelectronics among week's notable insider trades » 13:2302/1802/18/20
ADMS, CAR, K, SPB, UFI, UTX, PCTY, WMT, FMC, CCMP
Welcome to "Fly Insider,"…
Adamas Pharmaceuticals announces publication of EASE LID 2 trial results » 16:2002/1102/11/20
Adamas Pharmaceuticals announced the publication of final results from a two-year open-label study in Parkinson's disease, or PD, that demonstrated a sustained improvement in levodopa-induced dyskinesia, or LID, among patients using Gocovri extended-release capsules. The trial enrolled 223 patients, and results demonstrated that the treatment effect of Gocovri on motor complications, as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, or MDS-UPDRS, Part IV, was maintained for at least two years. This effect was seen in all subgroups, including those who continued treatment from prior double-blind trials, from placebo or amantadine immediate release, or IR, as well as a subgroup of patients with dyskinesia receiving deep brain stimulation, or DBS, treatment. Published online in the Journal of Parkinson's Disease, the new paper shares results from the 223-participant study. The EASE LID 2 study was designed to reflect real-world treatment conditions by including patients with DBS implants and those switching from amantadine IR, while also allowing study physicians to adjust patient's other PD medications as needed during the study. Overall the median treatment duration for trial participants was 1.9 years. In total, 13.9% discontinued the study because of adverse events considered to be related to Gocovri. All patients who received at least one dose of Gocovri were included in the safety analyses, which demonstrated findings broadly consistent with the phase III trials and product labeling. Common adverse events were falls, hallucinations, peripheral edemas, constipation and urinary tract infections.
Adamas announces departure of CMO Rajiv Patni 09:4501/0801/08/20
Adamas announces departure of CMO Rajiv Patni 09:2301/0801/08/20
Adamas announces departure of General Counsel, CBO, CCO Jennifer Rhodes 09:2201/0801/08/20
Adamas Pharmaceuticals sees Q4 GOCOVRI product sales $16.3M 09:2101/0801/08/20
Adamas Pharmaceuticals expects to engage FDA on ADS-5102 in 1H20 » 09:2001/0801/08/20
Adamas expects to engage…
Adamas expects to engage with the FDA in the first half of 2020 to discuss a potential regulatory pathway for ADS-5102 for multiple sclerosis patients with walking impairment based on data from the INROADS Phase 3 trial.
Adamas Pharmaceuticals aims to advance GOCOVRI performance in 2020 » 09:2001/0801/08/20
In 2020, Adamas plans to…
In 2020, Adamas plans to advance GOCOVRI performance through: Effective differentiation of GOCOVRI by communicating its unique clinical profile to drive health care provider adoption under experienced commercial leadership; Increased demand for GOCOVRI by elevating the urgency to treat dyskinesia and OFF in Parkinson's disease through education about their disruptive impact on patients, both directly and through partnerships with advocacy organizations; and Reducing barriers to access and improving fulfillment to provide an enhanced customer experience, while maintaining strong persistence on GOCOVRI.